News for FibroGen, Inc. (FGEN.MX)

SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. ( FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual He

FG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancerInitiation of

Total Revenue (Q4 2024): $3.1 million, down from $3.6 million in Q4 2023.Total Revenue (Full Year 2024): $29.6 million, down from $46.8 million in 2023.Develop

Mar 17, 2025 / 09:00PM GMTOperator Hello, everyone, and welcome to the FibroGen fourth quarter and full year 2024 earnings conference call. (Operator Instructio

FibroGen, Inc. (NASDAQ:FGEN) Q4 2024 Earnings Conference Call March 17, 2025 5:00 PM ETCompany ParticipantsJoanne Greller - LifeSci AdvisorsThane Wettig -...

Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million Transaction expected to close by mid-2025 Upon close o

Revenue: $3.1 million for Q4 2024, falling short of the estimated $24.91 million.Earnings Per Share (EPS): Reported a net loss of $0.08 per share, better than

SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. ( FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17

**media[556123]**

Sale of FibroGen China: Announced sale to AstraZeneca for approximately $160 million, enhancing financial stability.Enterprise Value: Transaction includes an e

**media[511571]**

- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief S

FibroGen, Inc. (NASDAQ:FGEN) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ETCompany ParticipantsDavid DeLucia - VP, Corporate FP&A &...

Revenue: Total revenue for Q3 2024 was $46.3 million, marking a 15% increase year-over-year, driven by strong performance in China.Net Loss: Reported a net los

FibroGen to Report Third Quarter 2024 Financial Results

Total Revenue: $50.6 million for Q2 2024, a 14% increase year-over-year.Roxadustat Net Product Revenue in China: $49.6 million for Q2 2024, a 108% increase yea

Aug 06, 2024 / 09:00PM GMTOperator Good day and welcome to the FibroGen second quarter 2024 earnings conference call. (Operator Instructions) Please note this e

The increase in emerging industries and the increasing investment in developing advanced technologies are opportunities for liver fibrosis market growth....

FibroGen, Inc. (NASDAQ:NASDAQ:FGEN) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ETCompany ParticipantsDavid DeLucia - CFA Vice President,...